Aripiprazole: Efficacy and tolerability profile of a novel-acting atypical antipsychotic

Drugs of Today

Volumn 39, Issue 2, 2003, Pages 145-151

  Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; KETOCONAZOLE; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; QUINIDINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; ZIPRASIDONE;

AGRANULOCYTOSIS; ANIMAL EXPERIMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MANIA; META ANALYSIS; NEGATIVE SYNDROME; NONHUMAN; POSITIVE SYNDROME; RAT; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; HUMANS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0037321460     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.2.799421     Document Type: Review

References (34)

1. Sartorius, N., Fleischhacker, W.W., Gjerris, A. et al. The usefulness and uses of second generation antipsychotic medications. Curr Opin Psychiatry 2002, (Suppl.).
2. Procyshyn, R., Thompson, D., Tse, G. Pharmacoeconomics of clozapine, risperidone and olanzapine: A review of the literature. CNS Drugs 2000, 13: 47-76.
3. Geddes, J., Freemantle, N., Harrison, P. et al. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and regression analysis. BMJ 2000, 321: 1371-6.
4. Glazer, W.M. Extrapyramidal side effects, tardive dyskinesia, and the concept of schizophrenia. J Clin Psychiatry 2000, 61: 16-21.
5. Csernansky, J.G., Mahmoud, R., Brenner, R. et al. The Risperidone User 79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med 2002, 346: 16-22.
6. Casey, D.E. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998, 59 (3, Suppl): 31-7.
7. Kinon, B. Olanzapine treatment of movement disorders. Presentation at the Annual Meeting of the American Psychiatric Association, Philadelphia, USA, May 2002.
8. www.CATIE.org
9. www.CAFE.org
10. Blackburn, G. Weight gain and antipsychotic medications. J Clin Psychiatry 2000, 61: 36-42.
11. Allison, D.B., Mentore, J.L., Moonseong, H. et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
12. Welch, R., Chue, P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000, 25: 154-60.
13. Lesem, M.D., Zajecka, J.M., Swift, R.H., Reeves, K.R., Harrigan, E.P. Intramuscular ziprasidone, 2 mg versus 10 mg, in the tients. J Clin Psuchitary 2001, 62 (Suppl. 2): 12-6.
14. Haupt, D.W., Newcomer, J.W. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001, 62: 15-26.
15. 1A receptor. Eur J Pharmacol 2002, 441: 137-40.
16. Kane, J.M., Carson, W.H., Saha, A.R. et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002, 63: 763-71.
17. Creese, I., Burt, D.R., Snyder, S. Dopamine receptor binding predicts clinical and pharmacological properties of antischizophrenic drugs. Science 1976, 192: 481-3.
18. Kapur, S., Remmington, G. Dopamine D2 receptors and their role in atypical antipsychotic action: Still necessary and maybe even sufficient. Biol Psychiatry 2001, 50: 873-83.
19. Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1: "Goldilocks" actions at dopamine receptors. J Clin Psychiatry 2001, 62: 841-2.
20. Stahl, S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: Illustrating their mechanism of action. J Clin Psychiatry 2001, 62: 923-4.
21. Altar, C.A., Kikuchi, T., Hirose, T., Tottori, K. The antipsychotic aripiprazole: A presynaptic D2 autoreceptor agonist that blocks postsynaptic agonist actions. Presentation at the American College of Neuropsychopharmacology, Puerto Rico, December 1998.
22. nd Collegium Internationale Neuropsychopharmacologium Congress, Brussels, Belgium, July 2000.
23. Potkin, S., Carson, W.H., Saha, A.R., McQuade, R.D. et al. A comparison of aripiprazole versus risperidone in patients with schizophrenia. Arch Gen Psychiatry 2003, in press.
24. Carson, W.H., Saha, A.R., McQuade, R.D. et al. A open-labeled extension study of aripiprazole. Presentation at the Annual Meeting of the American Psychiatric Association, Philadelphia, May 2002.
25. Carson, W.H., Saha, A.R., McQuade, R.D. et al. A maintenance study of aripiprazole. Presentation at the American College of Neuropsychopharmacology, Puerto Rico, December 2002.
26. Keefe, R.S.E., Silva, S.G., Perkins, D.O., Lieberman, J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophr Bull 1999, 25: 201-22.
27. Harvey, P.D., Keefe, R.S.E. Studies of cognitive change in patients with schizophrenia following treatment with atypical antipsychotics. Am J Psychiatry 2001, 158: 176-84.
28. Cornblatt, B., Green, M.F., Carson, W. et al. A comparison of cognitive performance on aripiprazole versus olanzapine. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): S185.
29. Keck, P., Carson, W.H., Saha, R.A. et al. A placebo controlled trial of aripiprazole for the treatment of acute mania. Presentation at the Annual Meeting of the American Psychiatric Association, Philadelphia, May 2002.
30. Casey, D., Kujawa, M. et al. Switching from other antipsychotics to aripiprazole. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1): S187.
31. Carson, W.H., Stock, E., Saha, A.R. et al. Metaanalysis of the safety and tolerability of aripiprazole. Schizophr Res 2002, 53: 186-7.
32. Dickson, R., Glazer, W. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999, 35: 575-86.
33. Buckley, P.F. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 2001, 50: 912-24
34. Kelleher, J.P., Centorrino, F., Albert, M.J., Baldessarini, R.J. Advances in atypical antipsychotics for the treatment of schizophrenia: New formulations and new agents. CNS Drugs 2002, 16: 249-261.